Additionally  this guidance highlights the concept that a biocompatibility assessment should begin with a risk-based approach instead of immediately considering new biocompatibility testing If the risk assessment indicates that biocompatibility testing is warranted  new test-specific recommendations are included in this guidance to address common deficiencies identified in premarket submissions